journal article·2023-12Open access

Identification and Characterization of CD8+CD27+CXCR3− T Cell Dysregulation and Progression‐Associated Biomarkers in Systemic Lupus Erythematosus

Lulu Zhang, Fang Du, Qiqi Jin, Li Sun, Boqian Wang, Ziyang Tan, Xinyu Meng, Baozhen Huang, Yifan Zhan, Wenqiong Su, Rui Song, Chunmei Wu, Luonan Chen, Xiaoxiang Chen, Xianting Ding

Advanced Science· Volume 10· Issue 35

Abstract

Abstract Systemic Lupus Erythematosus (SLE) etiopathogenesis highlights the contributions of overproduction of CD4+ T cells and loss of immune tolerance. However, the involvement of CD8+ T cells in SLE pathology and disease progression remains unclear. Here, the comprehensive immune cell dysregulation in total 263 clinical peripheral blood samples composed of active SLE (aSLE), remission SLE (rSLE) and healthy controls (HCs) is investigated via mass cytometry, flow cytometry and single‐cell RNA sequencing. This is observed that CD8+CD27+CXCR3− T cells are increased in rSLE compare to aSLE. Meanwhile, the effector function of CD8+CD27+CXCR3− T cells are overactive in aSLE compare to HCs and rSLE, and are positively associated with clinical SLE activity. In addition, the response of peripheral blood mononuclear cells (PBMCs) is monitored to interleukin‐2 stimulation in aSLE and rSLE to construct dynamic network biomarker (DNB) model. It is demonstrated that DNB score‐related parameters can faithfully predict the remission of aSLE and the flares of rSLE. The abundance and functional dysregulation of CD8+CD27+CXCR3− T cells can be potential biomarkers for SLE prognosis and concomitant diagnosis. The DNB score with accurate prediction to SLE disease progression can provide clinical treatment suggestions especially for drug dosage determination.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Systemic Lupus Erythematosus Research · Atherosclerosis and Cardiovascular Diseases · T-cell and B-cell Immunology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Rheumatology Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital and School of Biomedical Engineering Shanghai 200030 China

State Key Laboratory of Oncogenes and Related Genes Institute for Personalized Medicine School of Biomedical Engineering Shanghai Jiao Tong University Shanghai 200001 China

Key Laboratory of Systems Biology Center for Excellence in Molecular Cell Science Shanghai Institute of Biochemistry and Cell Biology Chinese Academy of Sciences Shanghai 200031 China

University of Chinese Academy of Sciences Beijing 100049 China

School of Life Science and Technology ShanghaiTech University Shanghai 201210 China

Department of Rheumatology and Immunology The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000 China

Science for Life Laboratory Department of Women's and Children's Health Karolinska Institutet Solna 17121 Sweden

Department of Chemical Pathology Li Ka Shing Institute of Health Sciences Faculty of Medicine The Chinese University of Hong Kong Hong Kong 999077 China

Drug Discovery Shanghai Huaota Biopharmaceutical Co. Ltd. Shanghai 200131 China

Nantong First People's Hospital Affiliated Hospital 2 of Nantong University Nantong Hospital of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Key Laboratory of Systems Health Science of Zhejiang Province School of Life Science Hangzhou Institute for Advanced Study University of Chinese Academy of Sciences Chinese Academy of Sciences Hangzhou 310024 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (75)

Show source-provided references
1. 10.1056/NEJMcibr110708510.1056/NEJMcibr1107085 ↗
2. 10.1016/j.cpha.2020.08.00510.1016/j.cpha.2020.08.005 ↗
3. 10.1002/advs.20200443310.1002/advs.202004433 ↗
4. 10.1038/nrrheum.2016.18610.1038/nrrheum.2016.186 ↗
5. 10.1038/s41590-019-0466-210.1038/s41590-019-0466-2 ↗
6. 10.1016/j.immuni.2009.09.00210.1016/j.immuni.2009.09.002 ↗
7. 10.1038/nrdp.2016.3910.1038/nrdp.2016.39 ↗
8. 10.1002/art.4038010.1002/art.40380 ↗
9. 10.1002/art.2074510.1002/art.20745 ↗
10. 10.1056/NEJMra120540610.1056/NEJMra1205406 ↗
11. 10.3389/fimmu.2013.0008810.3389/fimmu.2013.00088 ↗
12. 10.1136/annrheumdis-2013-20434310.1136/annrheumdis-2013-204343 ↗
13. 10.1126/science.119870410.1126/science.1198704 ↗
14. 10.1073/pnas.132140511110.1073/pnas.1321405111 ↗
15. 10.1038/nbt.259410.1038/nbt.2594 ↗
16. 10.1038/ni.354010.1038/ni.3540 ↗
17. 10.1111/imr.1265710.1111/imr.12657 ↗
18. 10.3389/fimmu.2018.0269210.3389/fimmu.2018.02692 ↗
19. 10.4049/jimmunol.168.11.553810.4049/jimmunol.168.11.5538 ↗
20. 10.1038/nm.213010.1038/nm.2130 ↗
21. 10.1084/jem.2016176010.1084/jem.20161760 ↗
22. 10.1002/eji.20164683710.1002/eji.201646837 ↗
23. 10.1093/eurheartj/ehx51710.1093/eurheartj/ehx517 ↗
24. 10.1038/s41580-018-0003-410.1038/s41580-018-0003-4 ↗
25. 10.1002/path.269710.1002/path.2697 ↗
26. 10.1111/bph.1522210.1111/bph.15222 ↗
27. 10.3389/fimmu.2014.0021410.3389/fimmu.2014.00214 ↗
28. 10.1126/science.abf197010.1126/science.abf1970 ↗
29. 10.1038/nature0663910.1038/nature06639 ↗
30. Katsuyama T. · Front Immunol · 2018 · 9
31. 10.1016/j.devcel.2017.02.00410.1016/j.devcel.2017.02.004 ↗
32. 10.1177/096120331349257810.1177/0961203313492578 ↗
33. 10.1016/j.jaut.2019.10237410.1016/j.jaut.2019.102374 ↗
34. 10.3389/fimmu.2019.0080510.3389/fimmu.2019.00805 ↗
35. 10.1080/15548627.2019.160354710.1080/15548627.2019.1603547 ↗
36. 10.1136/annrheumdis-2019-21539610.1136/annrheumdis-2019-215396 ↗
37. 10.1146/annurev-immunol-042617-05335210.1146/annurev-immunol-042617-053352 ↗
38. 10.1038/ni.331410.1038/ni.3314 ↗
39. 10.1016/j.immuni.2016.07.02210.1016/j.immuni.2016.07.022 ↗
40. 10.1038/s41467-018-03024-210.1038/s41467-018-03024-2 ↗
41. 10.1038/nprot.2015.02010.1038/nprot.2015.020 ↗
42. 10.1158/0008-5472.CAN-16-070710.1158/0008-5472.CAN-16-0707 ↗
43. 10.1016/j.immuni.2015.08.01710.1016/j.immuni.2015.08.017 ↗
44. 10.31138/mjr.28.1.410.31138/mjr.28.1.4 ↗
45. 10.1038/srep0034210.1038/srep00342 ↗
46. 10.1002/med.2129310.1002/med.21293 ↗
47. 10.1016/j.gene.2021.14599710.1016/j.gene.2021.145997 ↗
48. 10.1093/nar/gky113110.1093/nar/gky1131 ↗
49. 10.1038/8087710.1038/80877 ↗
50. 10.1084/jem.2004071710.1084/jem.20040717 ↗
51. 10.1016/j.semarthrit.2015.08.00110.1016/j.semarthrit.2015.08.001 ↗
52. 10.1016/j.autrev.2010.08.01510.1016/j.autrev.2010.08.015 ↗
53. 10.1084/jem.2003091610.1084/jem.20030916 ↗
54. 10.1681/ASN.200611123710.1681/ASN.2006111237 ↗
55. 10.1016/j.cell.2012.08.01510.1016/j.cell.2012.08.015 ↗
56. 10.1038/nri143510.1038/nri1435 ↗
57. 10.1126/sciimmunol.aat148210.1126/sciimmunol.aat1482 ↗
58. 10.1038/nri315610.1038/nri3156 ↗
59. 10.1073/pnas.95.12.695910.1073/pnas.95.12.6959 ↗
60. 10.4049/jimmunol.198.Supp.195.610.4049/jimmunol.198.Supp.195.6 ↗
61. 10.15252/embj.20179677110.15252/embj.201796771 ↗
62. 10.1172/JCI7393910.1172/JCI73939 ↗
63. 10.1136/annrheumdis-2018-21302810.1136/annrheumdis-2018-213028 ↗
64. 10.1016/S0140-6736(18)30485-910.1016/S0140-6736(18)30485-9 ↗
65. Li B. · Clin. Exp. Rheumatol. · 2014 · 32 · 705
66. 10.1002/art.178040092810.1002/art.1780400928 ↗
67. 10.1002/art.178035060610.1002/art.1780350606 ↗
68. 10.1021/ac901049w10.1021/ac901049w ↗
69. 10.1016/j.cell.2021.04.04810.1016/j.cell.2021.04.048 ↗
70. 10.1186/s13059-020-1950-610.1186/s13059-020-1950-6 ↗
71. 10.1038/s41592-019-0619-010.1038/s41592-019-0619-0 ↗
72. 10.1186/s13059-015-0844-510.1186/s13059-015-0844-5 ↗
73. Wu T. · Innovation · 2021 · 2
74. 10.1038/nmeth.440210.1038/nmeth.4402 ↗
75. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗